ABBV · News · 20260805N

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-08-05 · Importance 71 · Surprise 60

AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion, with the transaction priced at $135.11 per Apogee share. The acquisition is intended to expand AbbVie’s anti-inflammatory portfolio, including Apogee’s investigational zumilokibart, a potential competitor to Sanofi’s Dupixent. AbbVie launched a $10 billion bond sale and has also been reported to be seeking at least $8 billion of investment-grade debt to finance the transaction.

Key facts

• The announced AbbVie acquisition of Apogee Therapeutics represented a 49.5% premium. source
• Baron Capital's Baron Health Care Fund exited its position in Apogee Therapeutics after the company announced an agreement to be acquired by AbbVie for $135.11 per share. source